The anti-S antibody response after the first vaccine dose was greatly enhanced in individuals who had recovered from prior SARS-CoV-2 infection compared with those who were SARS-CoV-2 naive.
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Intermediate anticoagulation doses appear to be safe and effective as thromboprophylaxis in patients with high thrombotic risk active cancer.
Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.
Patients were randomly assigned 2:1 to copanlisib plus rituximab or placebo plus rituximab.
The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.
Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.
The cumulative 12-month incidence of venous thromboembolism was 12.7%.
Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.
